Search
Letrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. … [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Categories: Aromatase Inhibitors, Enzyme InhibitorsFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnWith the discovery of newer, non-steroidal and steroidal, aromatase inhibitors which were orally active and less expensive than formestane, formestane lost popularity. … Formestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity.
Categories: Aromatase Inhibitors, Enzyme InhibitorsExemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal
Categories: Aromatase Inhibitors, Enzyme InhibitorsAnastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigational[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer
Categories: Aromatase Inhibitors, Enzyme InhibitorsAminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAn aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.
Categories: Aromatase Inhibitors, Enzyme InhibitorsRibociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
Categories: Protein Kinase Inhibitors, Cytochrome P-450 CYP3A InhibitorsCamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigationalL64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors … [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist.
Categories: BCRP/ABCG2 Inhibitors, UGT1A1 InhibitorsTestolactone
go.drugbank.com/drugs/DB00894ApprovedWithdrawnAn antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Categories: Aromatase InhibitorsElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[A256828,A256863,L44948] Other types of endocrine therapy, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), may lead to drug resistance over time; therefore, the use
Categories: BCRP/ABCG2 Inhibitors, P-glycoprotein inhibitorsMinamestane
go.drugbank.com/drugs/DB20820ExperimentalThe usage of the INN stem '-mestane' in the name indicates that Minamestane is a aromatase inhibitor. Minamestane has a monoisotopic molecular weight of 297.17 Da.
Categories: Aromatase Inhibitors